Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Roula Younes

Nurse Practitioner, Acute Care Palm Desert, CA Nurse Practitioner

NPI 1760929897 CMS profile 10620449

36923 Cook St Ste 103, Palm Desert, CA 92211

Open in the dashboard

General payments

$4,170

148 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roula Younes of Palm Desert, CA is reported in the CMS Open Payments database as having received $4,170 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $440 11
2024 General $774 24
2023 General $1,338 60
2022 General $1,199 40
2021 General $419 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roula Younes
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Roula Younes were reported at $440. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Roula Younes Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $419 $123 $38–$327 $132
2022 $1,199 $130 $44–$369 $149
2023 $1,338 $144 $49–$410 $160
2024 $774 $146 $48–$433 $164
2025 $440 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $481 15 payments
  2. Janssen Biotech, Inc. $439 24 payments
  3. Cumberland Pharmaceuticals, Inc. $394 23 payments
  4. Paratek Pharmaceuticals, Inc. $363 21 payments
  5. La Jolla Pharmaceutical Company $335 10 payments
  6. Insmed, Inc. $283 8 payments
  7. Astellas Pharma US Inc $243 6 payments
  8. Merck Sharp & Dohme Corporation $234 11 payments
  9. Intuitive Surgical, Inc. $145 1 payment
  10. Shionogi Inc $131 2 payments
  11. Other $1,123 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,104 146 payments
  2. Education $66 2 payments
Products named General payments · program years 2021–2025
  1. SYMTUZA $489 25 payments
  2. VIBATIV $394 23 payments
  3. NUZYRA $363 21 payments
  4. XERAVA $319 9 payments
  5. DALVANCE $318 12 payments
  6. Arikayce $283 8 payments
  7. TEFLARO $260 9 payments
  8. DIFICID $216 10 payments
  9. Cresemba $167 3 payments
  10. ZERBAXA $149 7 payments
  11. Other $1,999 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

226

Median for Nurse Practitioner: 389

Drug cost

$104,288

Median for Nurse Practitioner: $21,885

Branded share of claims

44.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 13 $78,465
Daptomycin Generic 32 $6,734
Meropenem Generic 26 $4,815
Ertapenem Ertapenem Sodium Brand 28 $4,283
Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam Brand 22 $2,983
Cefepime Hcl Generic 18 $2,702
Micafungin Micafungin Sodium Brand 20 $1,611
Fluconazole Generic 30 $1,176
Ceftriaxone Ceftriaxone Sodium Brand 18 $1,109
Doxycycline Hyclate Generic 19 $411

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $123
$123 — —
DALVANCE
  • AbbVie, Inc. $83
$83 — —
TEFLARO
  • AbbVie, Inc. $83
$83 — —
Cresemba
  • Astellas Pharma US Inc $76
$76 — —
VIBATIV
  • Cumberland Pharmaceuticals, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record